Indications and Usage

- Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.
- Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

- Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.
Important Safety Information

Warnings and Precautions

- Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

—Patient with hemophilia A

WITH NOVOEIGHT®
YOUR PATIENTS ARE

ready to go

“I’m planning on working as a camp counselor this summer. Having a factor I can store and take with me is a huge relief.”

—Patient with hemophilia A

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.
Novoeight®—
A higher degree of stability

Novoeight® is the only factor VIII with stability up to 104°F for up to 3 months. The highest storage temperature for the longest duration.

Help your patients explore life up to 104°F—with the ability to store factor out of the fridge.

The only rFVIII with stability up to 104°F for up to 3 months:
- Novoeight®
- Kogenate®
- Nuwiq®
- Afstyla®
- ReFacto®
- Xyntha®
- Adynovate®
- Kovaltry®
- Advate®
- Jivi®
- Eloctate®

The longest duration of stability at 86°F:
- Novoeight®
- Kogenate®
- Nuwiq®
- Adynovate®
- ReFacto®
- Xyntha®
- Afstyla®
- Kovaltry®
- Novoeight®
- Advate®
- Jivi®
- Eloctate®

Important Safety Information

Warnings and Precautions (cont’d)

- Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight® in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors.

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.
Portability that fits into your patients’ lifestyle

Novoeight® offers quick reconstitution and multiple dose strengths

Designed for travel

Compact packaging for easy storage

Small kit holds up to a week’s worth of factor

Customizable case covers

Important Safety Information

Adverse Reactions

• The most frequently reported adverse reactions in clinical trials (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.
“When I’m out and doing physical activity, it’s helpful that Novoeight® is easy to take with me and use.”

—Vaughn, Novoeight® user

Indications and Usage

• Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

• Novoeight® is not indicated for the treatment of von Willebrand disease.

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.
Novoeight® PK profile achieves the needed peak levels of factor activity\(^1,12,13,\text{a,b}\)

Dosing and appropriate level of activity may be different from person to person. Appropriate dosing regimen and level of activity should be determined individually for each patient. Novoeight\(^\circ\) is approved for routine prophylaxis every other day or 3 times weekly. Please see Prescribing Information for complete dosing information.\(^1\)

**Speak with your patients about their activity and appropriate prophylaxis dosing schedule\(^{14}\)**

PK=pharmacokinetics.
\(\text{a}\) Applies similarly to other standard half-life replacement factor VIII products.
\(\text{b}\) Derived from Jiménez-Youst, et al. Mean PK profiles are based on patients aged ≥12 years who received a single 50 IU/kg intravenous dose of Novoeight\(^\circ\).\(^{13}\)

**Important Safety Information**

**Contraindications**

- Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight\(^\circ\) or its components, including hamster proteins

**Please see additional Important Safety Information throughout.**

**Please see accompanying Prescribing Information.**
WITH NOVOEIGHT®
YOUR PATIENTS CAN

take control
of their bleeds

“We’ve found Novoeight® to be the right therapy that fits with his life and effectively controls his bleeds.”

—Caregiver of patient with hemophilia A

Important Safety Information

Warnings and Precautions (cont’d)

- Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

- Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight® in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors.

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.
Proven effective across age groups

Novoeight® continued to reduce frequency of bleeds, demonstrating effective, long-term prophylaxis15,a

Median ABR

<table>
<thead>
<tr>
<th>All patients (0-65 years old)</th>
<th>Children (≤11 years old)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7 median bleeds per year1,a</td>
<td>3.0 median bleeds per year16,b</td>
</tr>
</tbody>
</table>

Results of an initial clinical trial studying the effectiveness and safety in children

Long-term safety trial

1.4 median bleeds per year1,a

The majority of patients continued in a safety extension trial

Important Safety Information

Adverse Reactions

- The most frequently reported adverse reactions in clinical trials (≥1%) were inhibitors in previously untreated patients (PUPs), injection site reactions, and pyrexia

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.
Proven reliable in PTPs who switched to Novoeight®

0 inhibitors were confirmed in one of the largest clinical trials with 1 previously treated patients

Established safety profile of Novoeight®

225 previously treated patients

88,000 exposure days

- In a clinical trial of PUPs, 42.9% developed inhibitors.

PUP=previously untreated patient; PTP=previously treated patient.

Novoeight® was shown to be safe in pivotal trials.
- Safety results consistent among adults, adolescents, and children
- No thromboembolic events occurred during the trials
- The most frequently reported adverse reactions in PTPs were injection site reactions (1.0%), and pyrexia (1.0%)
- Adverse reactions reported during postmarketing period were similar to those observed during clinical trials

Indications and Usage
- Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes
- Novoeight® is not indicated for the treatment of von Willebrand disease

Please see additional Important Safety Information throughout.
Please see accompanying Prescribing Information.
Consider the benefits of Novoeight® for your patients who are on the go

**PRODUCT ATTRIBUTES**

### rFVIII Comparison Guide*

<table>
<thead>
<tr>
<th>Choosing an rFVIII Product</th>
<th>Novoeight&lt;sup&gt;®1&lt;/sup&gt;</th>
<th>Adynovate&lt;sup&gt;®4&lt;/sup&gt;</th>
<th>Advate&lt;sup&gt;®3&lt;/sup&gt;</th>
<th>Afstyla&lt;sup&gt;®9&lt;/sup&gt;</th>
<th>Eloctate&lt;sup&gt;®2&lt;/sup&gt;</th>
<th>Jivi&lt;sup&gt;®5&lt;/sup&gt;</th>
<th>Kogenate&lt;sup&gt;® FS&lt;/sup&gt;7</th>
<th>Kovaltry&lt;sup&gt;®6&lt;/sup&gt;</th>
<th>Nuwiq&lt;sup&gt;®8&lt;/sup&gt;</th>
<th>Recombinate&lt;sup&gt;®21&lt;/sup&gt;</th>
<th>Xyntha&lt;sup&gt;®11&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage temperature up to 104°F for 3 months</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Storage temperature up to 86°F for 12 months</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greater than 4 hours of room temperature stability after reconstitution (at 86°F)</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixing device includes prefilled diluent syringe</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 or more vial sizes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diluent volume consistent across all vial sizes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest available diluent volume</td>
<td>4 mL</td>
<td>2 mL</td>
<td>2 mL</td>
<td>2.5 mL</td>
<td>3 mL</td>
<td>2.5 mL</td>
<td>2.5 mL</td>
<td>2.5 mL</td>
<td>5 mL</td>
<td>4 mL</td>
<td></td>
</tr>
</tbody>
</table>

The above table is not intended to compare the safety or efficacy of any of the products.

Data current as of December 5, 2018.

### Important Safety Information

**Contraindications**
- Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.
Ready to prescribe Novoeight®?

We can help your patients

Free trial program
• Talk to a NovoSecure™ Specialist
to find out if you’re eligible

Product Assistance Program
• Apply for the Product Assistance Program by calling 1-844-NOVOSEC
(1-844-668-6732) for more information

Co-pay assistance program
• Get help with co-pay costs for Novoeight®, if eligible

*Patients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. Product is provided at no cost to the patient and is not contingent on any product purchase. Physician and patient shall not: (1) bill any third party for the free product, or (2) sell the free product.

The Novo Nordisk Hemophilia & Rare Bleeding Disorders Product Assistance Program (PAP) is administered by NovoSecure™. To qualify for the PAP, patients must demonstrate financial need and be prescribed a Novo Nordisk factor product for an FDA indicated condition. Several factors are considered in evaluating financial need, including cost of living, size of household, and burden of total medical expenses. If the applicant qualifies under the PAP guidelines, a limited supply of the requested medication(s) will be shipped to the patient. Patients who qualify for PAP may be eligible to receive the prescribed Novo Nordisk product, for up to 1 year from the approval date. Product limits vary.

Eligibility and Restrictions:
In order to redeem this offer patient must have a valid prescription for the brand being filled. A valid Prescription ID is required on the prescription. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state health care program (such as Medicaid, Medicare, MediGap, VA, DOD, TRICARE, or any similar federal or state health care program) or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from, a commercial insurance plan. The brand and the prescription being filled must be covered by the patient’s commercial insurance plan. Offer excludes all cash-paying patients. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this card. Novo Nordisk’s Eligibility and Restrictions, and Offer Details may change from time to time, and for the most recent information, please visit https://www.mynovosecure.com/copayassistance/copay-form.html#/register-copay. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. This offer is valid in the United States and may be redeemed at participating retail pharmacies. Absent a change in Massachusetts law, effective July 1, 2019, the Savings Card will no longer be valid for residents of Massachusetts. Void where taxed, restricted, or prohibited by law. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Cash Discount Cards and other non-insurance plans are not valid as primary insurance under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. This Savings Card cannot be combined with any coupon, certificate, voucher, or similar offer. Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program. It is illegal to (or offer to) sell, purchase, or trade this offer. This program is managed by ConnectiveRx on behalf of Novo Nordisk. The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

Important Safety Information

Warnings and Precautions
• Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Please see accompanying Prescribing Information.

Support
References
**Important Safety Information**

**Warnings and Precautions**

- Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight® in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors.

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.